What is the typical dosing for Dulaglutide?

FDA-approved dosing. Common doses observed in research: 0.75mg weekly (starting), 1.5mg weekly, 3.0mg, 4.5mg weekly (higher doses). Duration: Long-term / chronic use. Administration: Subcutaneous injection weekly.

Weight Loss

Dulaglutide

Also known as: Trulicity

FDA Approved

Buy in shop

Dulaglutide from $281/kit

1 verified vendor, ≥99% purity, COAs included.

Compare prices

Key Facts: Dulaglutide

Category: Weight Loss
FDA Status: FDA Approved
Clinical Status: FDA Approved - Type 2 diabetes
Administration: Subcutaneous injection weekly
Typical Dose: 1.5-4.5 mg weekly
Frequency: Once weekly
Duration: Long-term / chronic use

Also Known As

Trulicity

Mechanism of Action

Dulaglutide consists of two GLP-1 analogs linked to a modified human IgG4 Fc fragment. This structure extends half-life to about 5 days, allowing weekly dosing. Works through standard GLP-1 receptor activation.

Research Summary

AWARD program showed significant A1C reduction and weight loss. REWIND trial demonstrated cardiovascular benefits in broader diabetic population. Generally shows 3-5% weight loss in trials.

Trial Progress:FDA Approved

Pre

III

FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical DosingⓘDoses commonly used by people in practice, based on community reports and anecdotal experience.

Community experience

Common Dose

1.5-4.5 mg weekly

Range

0.75-4.5 mg weekly

Frequency

Once weekly

FDA-approved as Trulicity. Titrate from 0.75 mg. Convenient once-weekly dosing.

Research DosingⓘDoses from published scientific studies and clinical trials. May include human or animal research.

Scientific studies

FDA-approved dosing

Doses from Studies

0.75mg weekly (starting)

FDA Approved Labeling - Prescribed dose ↗

1.5mg weekly

FDA Approved Labeling - Prescribed dose ↗

3.0mg, 4.5mg weekly (higher doses)

FDA Approved Labeling - Prescribed dose ↗

Duration

Long-term / chronic use

Administration

Subcutaneous injection weekly

Timing & Administration

Best Time to Take

Before bed or morning (fasted)

Follow specific peptide protocol

Food Recommendation

Take on empty stomach

Why This Timing?

GH-related peptides work best on an empty stomach to maximize growth hormone release.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

●Nausea
●Diarrhea
●Vomiting
●Abdominal pain
●Injection site reactions
●Hypoglycemia (with insulin/sulfonylureas)
●Pancreatitis
●Gallbladder problems
●BOXED WARNING: Thyroid C-cell tumors
●FDA approved (Trulicity)

References

Research This Peptide Further

PubMed ClinicalTrials.gov FDA.gov

Buy in shop

Dulaglutide from $281/kit

1 verified vendor, ≥99% purity, COAs included.

Compare prices

Frequently Asked Questions

What does Dulaglutide do?

An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.

How does Dulaglutide work?

Is Dulaglutide FDA approved?

Yes, Dulaglutide is FDA approved. FDA Approved - Type 2 diabetes

What are the side effects of Dulaglutide?

Reported side effects include: Nausea, Diarrhea, Vomiting, Abdominal pain, Injection site reactions. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Dulaglutide?

Community-reported common dose: 1.5-4.5 mg weekly (Once weekly). Range: 0.75-4.5 mg weekly. Administration: Subcutaneous injection weekly. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Dulaglutide or used in similar applications.

Semaglutide

FDA

A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

Weight Loss

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.

Weight Loss

Orforglipron

FDA

An oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo - the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.

Weight Loss

Liraglutide

FDA

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.

Weight Loss

Exenatide

FDA

The first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.

Weight Loss

Retatrutide

Clinical Trials

A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.

Weight Loss

How to Use Dulaglutide Dulaglutide Alternatives Compare with Similar Browse All Peptides

Want updates on Dulaglutide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides